| Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis C Giordano, G Stassi, R De Maria, M Todaro, P Richiusa, G Papoff, ... Science 275 (5302), 960-963, 1997 | 835 | 1997 |
| Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. MG Cifone, R De Maria, P Roncaioli, MR Rippo, M Azuma, LL Lanier, ... The Journal of experimental medicine 180 (4), 1547-1552, 1994 | 767 | 1994 |
| Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. I Cascino, G Fiucci, G Papoff, G Ruberti Journal of immunology (Baltimore, Md.: 1950) 154 (6), 2706-2713, 1995 | 572 | 1995 |
| Multiple pathways originate at the Fas/APO‐1 (CD95) receptor: sequential involvement of phosphatidylcholine‐specific phospholipase C and acidic sphingomyelinase in the … MG Cifone, P Roncaioli, R De Maria, G Camarda, A Santoni, G Ruberti, ... The EMBO journal 14 (23), 5859-5868, 1995 | 364 | 1995 |
| Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic … NKA Prasad, G Papoff, A Zeuner, E Bonnin, MD Kazatchkine, G Ruberti, ... The Journal of Immunology 161 (7), 3781-3790, 1998 | 346 | 1998 |
| An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. G Papoff, I Cascino, A Eramo, G Starace, DH Lynch, G Ruberti Journal of immunology (Baltimore, Md.: 1950) 156 (12), 4622-4630, 1996 | 316 | 1996 |
| Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor G Papoff, P Hausler, A Eramo, MG Pagano, G Di Leve, A Signore, ... Journal of Biological Chemistry 274 (53), 38241-38250, 1999 | 256 | 1999 |
| Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. E Puré, K Inaba, MT Crowley, L Tardelli, MD Witmer-Pack, G Ruberti, ... The Journal of experimental medicine 172 (5), 1459-1469, 1990 | 253 | 1990 |
| Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. I Cascino, G Papoff, R De Maria, R Testi, G Ruberti Journal of immunology (Baltimore, Md.: 1950) 156 (1), 13-17, 1996 | 250 | 1996 |
| Protection of CD95‐mediated apoptosis by activation of phosphatidylinositide 3‐kinase and protein kinase B P Häusler, G Papoff, A Eramo, K Reif, DA Cantrell, G Ruberti European journal of immunology 28 (1), 57-69, 1998 | 139 | 1998 |
| Requirement for CD8+ Cells in T Cell Receptor Peptide-Induced Clonal Unresponsiveness A Gaur, G Ruberti, R Haspel, JP Mayer, CG Fathman Science 259 (5091), 91-94, 1993 | 137 | 1993 |
| Constitutive expression of FasL in thyrocytes TA Stokes, M Rymaszewski, PL Arscott, SH Wang, JD Bretz, J Bartron, ... Science 279 (5359), 2015-2015, 1998 | 98 | 1998 |
| Soluble Fas/Apo-1 splicing variants and apoptosis I Cascino, G Papoff, A Eramo, G Ruberti Front Biosci 1, d12-d18, 1996 | 85 | 1996 |
| ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis M Compagnone, V Gatti, D Presutti, G Ruberti, C Fierro, EK Markert, ... Proceedings of the National Academy of Sciences 114 (50), 13254-13259, 2017 | 67 | 2017 |
| The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis M Tolomeo, L Dusonchet, M Meli, S Grimaudo, N D'Alessandro, G Papoff, ... Cell Death & Differentiation 5 (9), 735-742, 1998 | 65 | 1998 |
| Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines V Fustaino, D Presutti, T Colombo, B Cardinali, G Papoff, R Brandi, ... Oncotarget 8 (61), 103340, 2017 | 63 | 2017 |
| Harnessing the role of HDAC6 in idiopathic pulmonary fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors G Campiani, C Cavella, JD Osko, M Brindisi, N Relitti, S Brogi, ... Journal of medicinal chemistry 64 (14), 9960-9988, 2021 | 58 | 2021 |
| Development and Validation of a Luminescence-based, Medium-Throughput Assay for Drug Screening in Schistosoma mansoni C Lalli, A Guidi, N Gennari, S Altamura, A Bresciani, G Ruberti PLOS Neglected Tropical Diseases 9 (1), e0003484, 2015 | 55 | 2015 |
| Detection of polymorphisms within the FAS cDNA gene sequence by GC-clamp denaturing gradient gel eletrophoresis G Fiucci, G Ruberti Immunogenetics 39 (6), 437-439, 1994 | 54 | 1994 |
| Spiroindoline-capped selective HDAC6 inhibitors: design, synthesis, structural analysis, and biological evaluation AP Saraswati, N Relitti, M Brindisi, JD Osko, G Chemi, S Federico, A Grillo, ... ACS Medicinal Chemistry Letters 11 (11), 2268-2276, 2020 | 51 | 2020 |
Roberto TestiUniversity of Rome "Tor Vergata"Verified email at uniroma2.it
